GoAI
Get started
BridgeBio Oncology Therapeutics Inc. logo

BridgeBio Oncology Therapeutics Inc.

BBOT

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$8.895

−$0.185 · -2.04%

Aug 24, 10:09 AM ET

BBOT company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Hold

Wait — insufficient conviction to act

Valuation

51

Fair Value

Momentum

34

Weakening

Sentiment

63

Bullish

Risk resilience

40

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

BridgeBio Oncology Therapeutics functions as a clinical-stage biopharmaceutical firm dedicated to pioneering advanced small molecule treatments. These therapies are aimed at combating malignancies driven by RAS and PI3Kα, both frequently encountered oncogenes in human cancers. Initially established as an offshoot of BridgeBio Pharma, the company concentrates on precision oncology. Its developmental pipeline features several promising programs, including BBO-8520, BBO-10203, and BBO-11818, all specifically designed to modulate the KRAS and PI3K pathways. The company recently became publicly traded through a business combination with Helix Acquisition Corp. II. This strategic move successfully raised approximately $450 million, which will be utilized to further its clinical development initiatives. The leadership team comprises Dr. Eli Wallace as Chief Executive Officer and Dr. Pedro Beltran as Chief Scientific Officer.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Pedro J. Beltran
Listed since
Aug 12, 2025
Employees
92

Market position

Day range

Current $8.895

52-week range

Current $8.895

Open
$9.10
Previous close
$9.08
Volume
24.99K
0.06× average
Average volume
404.76K
Average daily volume
Market cap
712.55M USD
Beta
0.36
Market reference 1
50-day average
$8.4525
+5.24% above average
200-day average
$9.9587
-10.68% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

P/E (TTM)
-0.01×
P/B (TTM)
0×
P/S (TTM)
0×
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%

Financial health

Debt / equity
0.01×

Financial statements

Income trends

Operating income

−145.82M USD-80.33%

Net income

−134.04M USD-80.47%
Income trends across reported periods14.58M USD−43.75M USD−102.07M USD−160.4M USDOperating income, FY2021: −43.36K USDOperating income, FY2022: −3.52K USDOperating income, FY2023: −64.77M USDOperating income, FY2024: −80.86M USDOperating income, FY2025: −145.82M USDNet income, FY2021: −43.36K USDNet income, FY2022: −3.52K USDNet income, FY2023: −64.7M USDNet income, FY2024: −74.28M USDNet income, FY2025: −134.04M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −43.36K USD. Operating income FY2022 −3.52K USD. Operating income FY2023 −64.77M USD. Operating income FY2024 −80.86M USD. Operating income FY2025 −145.82M USD. Net income FY2021 −43.36K USD. Net income FY2022 −3.52K USD. Net income FY2023 −64.7M USD. Net income FY2024 −74.28M USD. Net income FY2025 −134.04M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Research and development121.2M USD73.11M USD56.29M USD——
Selling, general, and administrative24.62M USD7.76M USD8.49M USD3.52K USD43.36K USD
Operating expenses145.82M USD80.86M USD64.77M USD3.52K USD43.36K USD
Interest income11.34M USD8.46M USD72K USD——
Depreciation and amortization610K USD208K USD92K USD3.52K USD74.33K USD
Operating income−145.82M USD−80.86M USD−64.77M USD−3.52K USD−43.36K USD
Net income−134.04M USD−74.28M USD−64.7M USD−3.52K USD−43.36K USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
40%
2 beats, 3 misses, 0 met estimates
Average EPS surprise
-36.89%
5 comparable reports
Latest EPS result
-0.71
Estimate -0.57 · Miss by 24.81%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates4.3-15.91-36.12-56.33Q1 '25No estimateQ2 '25No estimateQ3 '25MissQ4 '25MissQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 11, 2025: actual 0.12, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 15, 2025: actual -52.15, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 1, 2025: actual -50.35, estimate -42.45, surprise -18.60%, Miss. Q4 2025, reported Nov 12, 2025: actual -1.03, estimate -0.382, surprise -169.87%, Miss. Q1 2026, reported Mar 5, 2026: actual -0.49, estimate -0.633, surprise +22.60%, Beat. Q2 2026, reported May 12, 2026: actual -0.48, estimate -0.512, surprise +6.24%, Beat. Q3 2026, reported Aug 11, 2026: actual -0.705, estimate -0.565, surprise -24.81%, Miss. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.56, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$23.00

158.57% upside
Past 12 months12-month forecastHigh $23.00Average $23.00Low $23.00

Rating distribution

4 ratings

Limited analyst sample: 4 ratings. Interpret the distribution with caution.

Strong buy00%
Buy4100%
Hold00%
Sell00%
Strong sell00%

BBOT news

globenewswire.com

BridgeBio Oncology Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc., or BBOT (NASDAQ: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today…

Read source
globenewswire.com

BBOT Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing of BBO-11818 in combination with cetuximab and after the end of the quarter, initiated dosing of BBO-11818 in…

Read source
defenseworld.net

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) Receives $24.80 Average PT from Brokerages

Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) have earned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat Ratings…

Read source
seekingalpha.com

BridgeBio Oncology Therapeutics: KRAS Program Data Due 2H26 May Reignite Bullish Sentiment

BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supported by three promising KRAS/RAS-targeted drug candidates. BBOT's lead asset, BB-8520, showed a 65% objective response rate…

Read source

BBOT peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

ETFs holding BBOT

Funds reporting this stock among their holdings, ordered by reported position size.

Vanguard Morningstar Total Stock Market ETF logoVanguard Morningstar Total Stock Market ETFVTI
Market value
11.51M
Weight
0.00%
AUM
2.3T USD
Expense ratio
0.03%
Price / 1D
$376.75-0.39%
State Street SPDR S&P Biotech ETF logoState Street SPDR S&P Biotech ETFXBI
Market value
7.75M
Weight
0.07%
AUM
11.39B USD
Expense ratio
0.35%
Price / 1D
$162.27-2.09%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
4.45M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.72-0.74%
iShares Biotechnology ETF logoiShares Biotechnology ETFIBB
Market value
2.91M
Weight
0.03%
AUM
10.75B USD
Expense ratio
0.44%
Price / 1D
$210.67-1.35%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
2.05M
Weight
0.01%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.415-1.21%
Tema Oncology ETF logoTema Oncology ETFCANC
Market value
880.31K
Weight
0.41%
AUM
215.38M USD
Expense ratio
0.99%
Price / 1D
$43.905-1.54%
Virtus Biotech Clinical Trials ETF logoVirtus Biotech Clinical Trials ETFBBC
Market value
364.17K
Weight
0.71%
AUM
51.68M USD
Expense ratio
0.65%
Price / 1D
$53.06-2.58%
Direxion Daily S&P Biotech Bull 3X Shares logoDirexion Daily S&P Biotech Bull 3X SharesLABU
Market value
307.74K
Weight
0.05%
AUM
—
Expense ratio
—
Price / 1D
$297.42-6.24%

Continue in GoAI

Research BBOT

research.disclaimer